[ad_2]
NEW YORK, Sept. 13, 2023 /PRNewswire/ — The women’s health diagnostics market size is expected to grow by USD 13.35 billion from 2022 to 2027. In addition, the momentum of the market will progress at a CAGR of 7.93% during the forecast period, according to Technavio Research. The market has been segmented by application (Breast cancer testing, Infectious disease testing, STD testing, Cervical cancer testing, and Others), end-user (Hospitals and clinics, Diagnostic and imaging centers, and Home care settings), and geography (North America, Europe, Asia, and Rest of World (ROW)). North America is estimated to contribute 41% to the growth of the global market. Much of the market growth in this region is due to technology adoption, increased healthcare spending, raised incidence of diseases such as cancer, and increased awareness of breast cancer screening and diagnosis. Cancer is one of the most common chronic diseases among people in this region. According to the CDC, breast cancer is one of the most common cancers in women and the second leading cause of cancer death among women in the US. Hence, such factors are expected to drive market growth in the region during the forecast period. This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read FREE PDF Sample Report
Company Profile:
Abbott Laboratories, Becton Dickinson and Co., Bio Rad Laboratories Inc., Danaher Corp., Exact Sciences Corp., F. Hoffmann La Roche Ltd., FUJIFILM Corp., GE Healthcare Technologies Inc., Hologic Inc., Illumina Inc., Invitae Corp., Myriad Genetics Inc., Natera Inc., PerkinElmer Inc., QIAGEN NV, Quest Diagnostics Inc., Quidelortho Corp., Siemens AG, Thermo Fisher Scientific Inc., and Koninklijke Philips N.V.
- Abbott Laboratories, Becton Dickinson and Co. – The company offers women’s health diagnostics such as menstrual medicine called Duphaston and Iberet Folic 500.
To gain access to more vendor profiles available with Technavio, buy the report!
Women’s Health Diagnostics Market: Segmentation Analysis
The market share growth by the breast cancer testing segment will be significant during the forecast period. A biopsy is the only reliable way to identify breast cancer. Biopsy samples are analyzed in a laboratory to determine if they contain cancer cells. The type of cell involved in breast cancer, its invasiveness (grade), and whether the cancer cell has hormone receptors or other receptors that can affect treatment options are all determined by biopsy analysis.
Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a FREE PDF Sample Report
“Besides analyzing the current market scenario, our report examines historic data from 2017 to 2021”- Technavio
Women’s Health Diagnostics Market: Driver & Trend:
- Increasing prevalence of STDs
- Increasing prevalence of breast cancer
- Increasing infertility rate in women
The increasing prevalence of STDs is the key factor driving the growth of the market. STDs are caused by the transmission of different types of bacteria, viruses, and parasites during the exchange of vaginal secretions. Syphilis, gonorrhea, chlamydia, hepatitis B, genital herpes, and HIV are among the many sexually transmitted diseases. The main causes of pelvic inflammatory disease and infertility in women are gonorrhea and chlamydia. Providers around the world strive to offer a wide variety of drugs for STD testing.
Identify key trends, drivers, and challenges in the market. Download FREE sample to gain access to this information.
Related Reports:
The companion diagnostics market is estimated to grow at a CAGR of 22.59% between 2022 and 2027. The market size is forecast to increase by USD 11,029.63 million. Furthermore, this report extensively covers market segmentation by end-user (life science, health centers, and others), indication (oncology, neurology, and others), and geography (North America, Europe, Asia, and the Rest of the World (ROW)). The rising use of personalized medicine is a key factor driving market growth during the forecast period.
The cancer diagnostics market is estimated to grow at a CAGR of 11.3% between 2022 and 2027. The market size is forecast to increase by USD 12,626.21 million. Furthermore, this report extensively covers market segmentation by end-user (hospitals and clinics, and diagnostic laboratories), type (IVD, imaging, and IDT), and geography (North America, Europe, APAC, and the Rest of the World (ROW)). The high prevalence of cancer is a key factor driving market growth during the forecast period.
What are the key data covered in this women’s health diagnostics market report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the women’s health diagnostics market between 2022 and 2027.
- Precise estimation of the women’s health diagnostics market size and its contribution to the market in focus on the parent market
- Accurate predictions about upcoming trends and changes in consumer behavior
- Growth of the women’s health diagnostics market across North America, Europe, Asia, and ROW
- A thorough analysis of the market’s competitive landscape and detailed information about vendors
- Comprehensive analysis of factors that will challenge the growth of womens health diagnostics market vendors.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by End-User
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/womens-health-diagnostics-market-to-grow-by-usd-13-35-billion-from-2022-to-2027–north-america-to-account-for-41-of-market-growth–technavio-301926904.html
SOURCE Technavio
Source link
[ad_2]
The content is by PR Newswire. Headlines of Today Media is not responsible for the content provided or any links related to this content. Headlines of Today Media is not responsible for the correctness, topicality or the quality of the content.
[ad_2]